Insider Trading Activity For Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Patrick G Enright , Director of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) reportedly Sold 351 shares of the company’s stock at an average price of 148.4 for a total transaction amount of $52,088.40 SEC Form
Insider Trading History For Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Analyst Ratings For Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
These are 3 Hold Ratings, 16 Buy Ratings .
The current consensus rating for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is Buy (Score: 2.84) with a consensus target price of $182.84 , a potential (25.16% upside)
Analyst Ratings History For Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
- On 4/1/2016 Northland Securities Reiterated Rating Outperform with a price target of $175.00
- On 4/5/2016 Canaccord Genuity Reiterated Rating Buy with a price target of $170.00
- On 1/18/2017 Barclays PLC Reiterated Rating Overweight with a price target of $200.00
- On 1/18/2017 Goldman Sachs Group, Inc. (The) Reiterated Rating Buy with a price target of $170.00
- On 1/19/2017 SunTrust Banks, Inc. Reiterated Rating Buy with a price target of $210.00
- On 2/16/2017 Guggenheim Reiterated Rating Buy
- On 2/22/2017 Evercore ISI Initiated Coverage of rating Buy with a price target of $160.00
Recent Trading Activity for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Shares of Jazz Pharmaceuticals PLC closed the previous trading session at 146.09 up +0.09 0.06% with 297,724 shares trading hands.